CD24 and breast carcinoma: We performed CMAP analyses of gene expression datasets comparing MCF-10A CD44+/CD24− with CD44−/CD24+ subpopulation20, tumorigenic (CD44+/CD24−/Lin−) cells versus non-tumorigenic cells from primary tumors21, genes up or down-regulated in pooled normal and metastatic CD44+ breast cancer cells versus normal and metastatic CD24+ cells22, 23, and transformed SSEA1+ CSC fibroblasts versus transformed SSEA1− fibroblasts23.